Can I Take Ashwagandha with Metformin?

What Kind of Interaction Exists Between Ashwagandha and Metformin?

The interaction is pharmacodynamic, not pharmacokinetic. Ashwagandha (Withania somnifera) does not appear to meaningfully inhibit or induce the cytochrome P450 enzymes or renal transporters (OCT1, OCT2, MATE1) through which metformin is absorbed and cleared [1]. That means ashwagandha is unlikely to raise or lower metformin blood levels in the way that drugs like cimetidine can.

The concern instead is that both agents work on blood glucose through different but convergent pathways, and their effects can add up.

How Metformin Lowers Glucose

Metformin activates AMP-activated protein kinase (AMPK) in hepatocytes, suppressing hepatic glucose output by roughly 30% and improving peripheral insulin sensitivity [2]. At standard doses of 500 to 2,000 mg daily, it reduces HbA1c by approximately 1.0 to 2.0 percentage points as monotherapy [3].

How Ashwagandha Affects Blood Sugar

Ashwagandha's hypoglycemic activity appears to involve multiple pathways: enhanced insulin secretion from pancreatic beta cells, increased GLUT4 translocation in skeletal muscle, and reduced oxidative stress that impairs glucose uptake [4]. A randomized, double-blind trial (N=60) published in Medicine found that 600 mg/day of ashwagandha root extract for 12 weeks reduced fasting blood glucose by 13.5 mg/dL compared to placebo (P<0.05) [5].

What "Additive Pharmacodynamic Effect" Means Clinically

When two agents both lower glucose, the combined drop can exceed what either achieves alone. For most type 2 diabetic patients on metformin monotherapy whose HbA1c is well above target, this additive effect might actually be welcome. For patients already near or at glycemic target, or for those on intensified regimens that include sulfonylureas or insulin alongside metformin, the addition of ashwagandha 600 mg/day could tip fasting glucose below 70 mg/dL.

The Cortisol Angle: Does It Matter for Metformin Users?

Ashwagandha is classified as an adaptogen, a compound that modifies the body's hormonal stress response. Its best-documented human effect is a reduction in serum cortisol. A 60-day RCT (N=64) published in the Indian Journal of Psychological Medicine reported a 27.9% reduction in serum cortisol in the ashwagandha group vs. 7.9% in the placebo group (P<0.0001) [6].

Why Cortisol Reduction Matters for Glucose Control

Cortisol raises blood glucose by stimulating hepatic gluconeogenesis and antagonizing insulin at the receptor level [7]. Chronically elevated cortisol is one mechanism behind stress hyperglycemia and contributes to insulin resistance in type 2 diabetes. Lowering cortisol through ashwagandha could therefore improve insulin sensitivity independently of the direct beta-cell and GLUT4 effects described above.

This is a second pharmacodynamic pathway through which ashwagandha and metformin could produce additive glucose lowering, one that operates through the HPA axis rather than through AMPK or insulin secretion.

What This Means Practically

Patients with stress-driven hyperglycemia spikes may see disproportionately large glucose improvements when they add ashwagandha. Monitoring fasting glucose weekly for the first four weeks after initiating the supplement is a reasonable precaution.

Ashwagandha and the Thyroid: A Separate Watch-Point

Ashwagandha has demonstrated thyroid-stimulating activity in human trials. A randomized, double-blind study (N=50) published in the Journal of Alternative and Complementary Medicine found that 600 mg/day of ashwagandha root extract for 8 weeks significantly increased serum T3 (triiodothyronine) and T4 (thyroxine) vs. Placebo (P<0.05) [8].

Why This Matters Alongside Metformin

Metformin itself has no direct thyroid pharmacology, so this is not a metformin-specific concern. It is, however, relevant for the patient population. Many people with type 2 diabetes also have hypothyroidism (prevalence estimates range from 6% to 13% in T2DM cohorts) [9] and take levothyroxine. Adding ashwagandha to a levothyroxine-plus-metformin regimen could raise circulating thyroid hormone and precipitate symptoms of hyperthyroidism: palpitations, insomnia, weight loss, or worsening glucose variability.

Monitoring Recommendation

If you take levothyroxine and want to add ashwagandha, recheck TSH and free T4 at 6 to 8 weeks after starting the supplement and report palpitations or unexplained weight changes to your provider promptly.

Does Ashwagandha Affect Testosterone and Sex Hormones? Relevance to Metformin Users

Ashwagandha has also been associated with increases in serum testosterone. A double-blind RCT (N=57) published in Fertility and Sterility reported that 675 mg/day of ashwagandha root extract (KSM-66) taken for 90 days increased serum testosterone by 17% compared to placebo in infertile men [10].

Who This Affects in a Metformin Context

Metformin is sometimes prescribed off-label for polycystic ovary syndrome (PCOS), where elevated androgens are already a concern [11]. In women with PCOS on metformin, the potential androgenic effect of ashwagandha is worth flagging with a prescriber before starting. The evidence for significant testosterone elevation in women is thin, but the caution is reasonable given the PCOS phenotype.

For men with type 2 diabetes on metformin who are also dealing with low testosterone secondary to obesity or insulin resistance, a modest testosterone increase from ashwagandha might be neutral or mildly beneficial. It is not a substitute for evaluation of hypogonadism.

Is There a Required Dose-Separation Window?

No mandatory separation window exists for this combination. Because the interaction is pharmacodynamic rather than pharmacokinetic, separating doses by one or two hours does not eliminate the glucose-lowering overlap. The practical implication is that consistent timing (taking both with meals) matters more for tolerability than strategic spacing.

Metformin is best taken with food to reduce GI side effects. Ashwagandha root extract is also better tolerated with food. Taking both with your largest meal of the day is a sensible default.

What the Evidence Base Actually Looks Like

Ashwagandha Alone in Type 2 Diabetes

A meta-analysis published in PLOS ONE (k=5 RCTs, N=238) examined ashwagandha supplementation in patients with diabetes or metabolic stress and found significant reductions in fasting blood glucose (weighted mean difference: -13.6 mg/dL, 95% CI -24.7 to -2.5) and HbA1c (weighted mean difference: -0.77%, P<0.05) [12].

No Dedicated Combination Trial Exists

No published RCT has specifically studied the ashwagandha-plus-metformin combination in humans as of mid-2025. The interaction framework HealthRX uses is therefore built from mechanistic overlap data, single-agent trials, and clinical pharmacology principles rather than from a dedicated combination study. This is a genuine gap in the evidence base that physicians should communicate to patients asking about this combination.

The Clinical Bottom Line on Evidence Quality

The evidence supporting ashwagandha as an adjunct glucose-lowering agent is promising but not practice-changing on its own. RCT sample sizes are small (N=50 to N=125), trial durations are short (8 to 16 weeks), and standardization of the extract varies. Calling ashwagandha a proven antidiabetic supplement would overstate the data. What the data do support is a biologically plausible pharmacodynamic interaction with metformin that warrants clinical awareness.

Who Should Be Most Cautious About This Combination?

Patients Already Near Glycemic Target

If your most recent HbA1c is below 7.0% on metformin alone, adding a supplement that reduces fasting glucose by an additional 13 to 14 mg/dL may push you into hypoglycemia territory, particularly overnight. This group should monitor fasting glucose closely for the first 4 weeks.

Patients on Multi-Drug Regimens

Patients combining metformin with sulfonylureas (glipizide, glimepiride), SGLT2 inhibitors, or insulin face a higher baseline hypoglycemia risk. Adding ashwagandha to these regimens without provider oversight is not advisable. A 2022 ADA Standards of Medical Care notes that hypoglycemia remains "the main limiting factor in the glycemic management of type 1 and type 2 diabetes" [13].

Patients with Thyroid Disease or Autoimmune Conditions

Ashwagandha has documented immunomodulatory activity. Patients with autoimmune thyroid disease (Hashimoto's, Graves'), lupus, rheumatoid arthritis, or multiple sclerosis should consult a physician before use, as immune stimulation could exacerbate disease activity [14].

Pregnant Patients

Pregnant patients with gestational diabetes sometimes use metformin off-label (or on-label, depending on jurisdiction). Ashwagandha has documented abortifacient effects in animal studies and is contraindicated in pregnancy [15]. This combination should be avoided entirely during gestation.

Monitoring Protocol If You Decide to Combine Both

A reasonable clinical monitoring framework for a patient adding ashwagandha to an existing metformin regimen looks like this:

• Baseline (before starting ashwagandha): fasting glucose, HbA1c, TSH, free T4 (if on levothyroxine or with thyroid history).
• Week 2 and Week 4: fasting glucose by home glucometer, daily if convenient. Log any episodes of glucose <70 mg/dL.
• Week 8 to 12: repeat fasting glucose and HbA1c. If HbA1c has dropped more than 0.5 percentage points, discuss metformin dose adjustment with your prescriber.
• Week 8 (thyroid subgroup): TSH and free T4 recheck for patients on levothyroxine.
• Ongoing: annual HbA1c as per American Diabetes Association guidelines for stable, well-controlled patients [13].

The ADA 2024 Standards of Care state: "In patients who are not meeting glycemic targets, HbA1c should be measured quarterly" [13]. If adding ashwagandha moves glucose enough to change your glycemic trajectory, quarterly measurement applies.

Practical Dosing Notes for Ashwagandha

Most studied doses in RCTs examining glucose and cortisol outcomes have ranged from 300 mg to 600 mg of root extract daily, typically standardized to 5% withanolides (e.g., KSM-66 or Sensoril). The 600 mg/day dose used in the Medicine trial that showed a 13.5 mg/dL fasting glucose reduction was taken as two 300 mg doses with meals [5].

Doses above 1,000 mg/day have not demonstrated proportionally greater glycemic benefit in the available literature, and GI side effects (nausea, loose stools) become more common above 600 mg/day.

There is no established minimum duration for glycemic effects, but the trials showing significant HbA1c reduction ran for at least 12 weeks. Expect 8 to 12 weeks before assessing whether the supplement has made a meaningful difference in glucose control.

Drug Interaction Databases: What They Say

The Natural Medicines database (subscription-required, referenced via NIH integration) rates the ashwagandha-metformin interaction as "moderate," citing additive hypoglycemic effects as the primary concern. The interaction is not flagged as contraindicated [16].

Mayo Clinic's drug interaction checker does not list a specific ashwagandha-metformin contraindication but notes that ashwagandha "may enhance the blood-glucose-lowering effect of antidiabetic drugs" [17].

Neither database identifies a pharmacokinetic mechanism, which is consistent with the mechanistic evidence reviewed above.

Talking to Your Doctor: What to Bring to the Appointment

Bring the specific supplement product (or its label) so your provider can see the extract type, standardization percentage, and dose. Ask your provider to review your most recent HbA1c and fasting glucose trend before deciding. If your provider is unfamiliar with ashwagandha, the 2020 meta-analysis in PLOS ONE [12] and the 2019 Medicine RCT [5] are reasonable starting points for a shared clinical conversation.

If you are already taking ashwagandha and have not told your prescriber, bring it up at your next visit. Changes in glucose control that are attributed to metformin dose adjustments may actually reflect the additive effect of the supplement.